AstraZeneca (AZN) Announces Significant PFS Data from LYNPARZA Phase III SOLO-2
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LYNPARZA (olaparib) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
